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Abstract
Background:  Despite well-studied tumor hypoxia in laboratory, little is known about the
association with other pathophysiological events in the clinical view. We investigated the
prognostic value of hypoxia-inducible factor-1 alpha (HIF-1alpha) in hepatocellular carcinoma
(HCC), and its correlations with inflammation, angiogenesis and MYC oncogene.
Methods: In a random series of 110 HCC patients, the mRNA of HIF-1alpha, inflammation related
factors (COX-2, MMP7 and MMP9), angiogenesis related factors (VEGF and PDGFRA) and MYC
in tumor tissue were detected by real-time RT-PCR and HIF-1alpha protein was assessed by
immunohistochemistry. The correlations between HIF-1alpha mRNA and the factors mentioned
previously, the relationship between HIF-1alpha and clinicopathologic features, and the prognostic
value were analyzed.
Results:  The expression of both HIF-1alpha mRNA and protein in HCC were independent
prognostic factors for overall survival (OS) (P = 0.012 and P = 0.021, respectively) and disease-free
survival (DFS) (P = 0.004 and P = 0.007, respectively) as well. Besides, the high expression of HIF-
1alpha mRNA and protein proposed an advanced BCLC stage and more incidence of vascular
invasion. The mRNA of HIF-1alpha had significantly positive correlations to that of COX-2,
PDGFRA, MMP7, MMP9, MYC, except VEGF. In addition to HIF-1alpha, COX-2 and PDGFRA
were also independent prognosticators for OS (P = 0.004 and P = 0.010, respectively) and DFS (P
= 0.010 and P = 0.038, respectively).
Conclusion: HIF-1alpha in HCC plays an important role in predicting patient outcome. It may
influence HCC biological behaviors and affect the tumor inflammation, angiogenesis and act in
concert with the oncogene MYC. Attaching importance to HIF-1alpha in HCC may improve the
prognostic and therapeutic technique.
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Background
HEPATOCELLULAR carcinoma (HCC) is the sixth most
common cancer and the third most common cause of
death from cancer worldwide, with increasing incidence
in western countries [1]. Surgical resection provides an
opportunity for cure, but the outcome remains dismal due
to frequent tumor recurrence. Recently, better apprecia-
tions of the role that tumor microenvironment plays in
tumor progression have bring a paradigm shift in devel-
oping strategies for cancer management. As a conse-
quence, renewed emphasis has been placed on key
features of the tumor microenvironment, in particular
hypoxia, leading us to explore hypoxia related parameters
for more accurate classification of this fetal disease.
As is well-recognized, hypoxia is a common mechanism
in HCC as the solid tumor owing to aberrant visualization
[2]. Accumulating data have shown that hypoxia can stim-
ulate proliferation[3], induce angiogenesis [4], accelerate
invasion [5] and is responsible for treatment resistance in
HCC [6]. The adaptation of HCC cells to tissue hypoxia is
of central importance for tumor progression, where
inducing the ubiquitous transcription factor of hypoxia-
inducible factor-1α (HIF-1α) expression appears to be a
critical step [7].
HIF-1α is a master regulator of essential adaptive
responses to hypoxia, whose expression and transcrip-
tional activity increasing exponentially with decreases in
levels of cellular oxygen. In tumors, HIF-1α regulates pro-
liferation, apoptosis, metastatic spread, and glucose
metabolism by acting as a transcription factor for crucial
proteins [8].
Previous studies have been focusing on the clinical signif-
icance as well as experimental models of HIF-1α in many
types of cancer, which have led to somewhat controversial
results [9,10]. On the basis of its unquestioned role as a
central regulator of tumor pathophysiology, elucidating
HIF-1α's prognostic value in HCC is of great clinical
importance, which may lead to better patient stratification
and provide rational for hypoxia targeted therapies.
Importantly, the presence of hypoxia is always associated
with and accompanied by inflammation and angiogen-
esis [11,12]. Specifically, HIF-1α and the oncogene MYC,
which is also a transcription factor, act in concert to "fine
tune" cancer cells' adaptive responses to hypoxic environ-
ments [13].
In the present study, we measured mRNA expression of
HIF-1α in tumor tissue from 110 randomly selected HCC
patients. We found that HIF-1α expression was associated
with aggressive phenotypes of HCC and could be an inde-
pendent prognostic factor for HCC patients after curative
hepatectomy. Meanwhile, we presented the real-time
reverse-transcriptase polymerise-chain-reaction (RT-PCR)
study in the same cohort of patients on a battery of core
genes which play important roles in inflammation (COX-
2, MMP7, MMP9) [14-16] and angiogenesis (VEGF, PDG-
FRA) [17,18], as well as MYC which was confirmed as a
key hypoxia regulator [19], to find the correlation of HIF-
1α with these factors that can also affect and reflect tumor
behaviors. These factors were selected for at least two of
the three aspects: being crucial in inflammation or angio-
genesis; being active in tumor metastasis or invasion;
being mechanistically related to hypoxia. At last, using in
situ immunostaining of HIF-1α protein, we got a further
confirmation of the clinical significance of this crucial fac-
tor.
Methods
Patients and Specimens
Under the following the inclusion and exclusion criteria:
(a) distinctive pathologic diagnosis of HCC, (b) without
anticancer treatment and distant metastases before sur-
gery, (c) underwent primary and curative resection for
HCC between 2002 and 2005, defined as macroscopically
complete removal of the tumor, as described previously
[20], and (d) with complete clinicopathologic and follow-
up data, about 2000 patients underwent hepatectomy at
Zhongshan Hospital, Fudan University between 2002 and
2005 were identified. Following approval by the Institu-
tional Review Board, a total of 110 patients in this time,
with available frozen tumor specimens from our prospec-
tively established tissue bank, were chosen randomly to
be entered in this retrospective study. The mean age of
patients was 52.4 years (range: 28-75) and all the patients
were classified with Barcelona Clinic Liver Cancer staging
system (BCLC stage) [21]. Informed consent was obtained
from all patients.
A diagnosis of recurrence was confirmed by an elevated
AFP level and typical imaging appearance in computed
tomography and/or magnetic resonance imaging scan
[20]. Overall survival (OS) was defined as the interval
from surgery and death. Disease-free survival time (DFS)
was defined as the interval from surgery to recurrence. The
data was censored on last follow-up for living patients or
for the patients in whom tumor recurrence was not diag-
nosed. The median follow-up time was 24.0 months
(range: 1.5-68.0 mon; SE: 1.49).
Real-time RT-PCR
Total RNA was isolated from each specimen with Trizol
reagent (Invitrogen, Carlsbad, CA) and then reverse tran-
scribed with the oligo dT primers and SuperScript RT (Inv-
itrogen). The PCR primers used were showed in Table 1.
Quantitative real-time RT-PCR was performed by using a
384-well ABI 7900 HT (Applied Biosystems, Foster City,BMC Cancer 2009, 9:418 http://www.biomedcentral.com/1471-2407/9/418
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CA). In particular, for a single gene, PCR amplifications of
all the 110 specimens were simultaneously performed on
the same 384-well plate in duplicate to avoid potential
variations. Duplicate RT-PCR samples in each assay were
collapsed by averaging.
Cycling parameters were as follows: 2 min at 50°C and 10
min at 95°C followed by 40 cycles of 30 sec at 95°C and
2 min at 60°C. The relative changes in gene expression
were calculated by the ΔΔCt method using the SDS 2.1
software according to the manufacturer's instructions
(Applied-Biosystems). The expression of each gene was
related to its expression in the reference RNA pool from
the 10 normal liver tissues used as a calibrator. To control
for variability in cDNA quantity, integrity, and individual
primer efficiency, data were normalized against two
housekeeping genes (TBP and HPRT) as we previously
described [22]. (See Additional file 1: Figure S1 for relative
mRNA expression of HIF-1α, COX-2, MMP7, MMP9,
VEGF, PDGFRA and MYC with the cut-off value deter-
mined by the X-tile software).
Tissue microarray and Immunohistochemistry
Tissue microarrays (TMA) were constructed as described
previously [23]. Triplicates of 1-mm-diameter cylinders
from representative areas of tumor center, away from
necrotic, hemorrhagic and major fibrotic areas, were
included in each case, along with different controls
(spleen, lymph node, artery and glioma), to ensure repro-
ducibility and homogenous staining of the slides. Serial
sections (4 μm thick) were placed on slides coated with 3-
aminopropyltriethoxysilane.
Immunohistochemical staining by the streptavidin-
biotin-peroxidase complex method was performed as pre-
viously described. Rabbit polyclonal antibody to HIF-1α
(ab65979; Abcam, Cambridge, UK) was used at a dilution
of 1:50. Briefly, sections were dewaxed, hydrated, and
washed. After neutralization of endogenous peroxidase
and microwave antigen retrieval, slides were preincubated
with blocking serum and then incubated overnight with
the primary Ab. Then, the sections were serially rinsed,
incubated with second antibodies, and treated with horse-
radish peroxidase-conjugated streptavidin. Reaction prod-
ucts were visualized with 3, 3'-diaminobenzidine
tetrahydrochloride and counterstained with hematoxylin.
For the negative control, the primary antibodies were
replaced with phosphate buffered saline.
The manual evaluation of HIF-1α expression involved
location and degree of reactivity. Location of expression
included not only the cell type but also that of the subcel-
lular localization (i.e., nucleus, cytoplasm). Degree of
expression was determined by assessing semiquantita-
tively percentage of positive nuclear staining cells in ran-
dom four fields of each core as well as evaluating for
cytoplasmic staining intensity in the entire disk. The final
result was classified as follows: I, no staining; II, nuclear
staining in less than 10% of cells and/or with weak cyto-
plasmic staining; III, nuclear staining in 10%-50% of cells
and/or with moderate cytoplasmic staining; IV, nuclear
staining in more than 50% of cells and/or with strong
cytoplasmic staining [24] In statistical analysis, the grades
I and II were considered to be low expression of HIF-1α
protein, with III and IV as high expression [25]. (See Addi-
tional file 2: Table S1 for degree of HIF-1α immunohisto-
chemical staining)
Two independent investigators blind to the clinicopatho-
logic data assessed the immunohistochemistry. When
independent scoring of a case differed, the case was
rechecked, and the final score was determined by recount-
ing HIF-1α positive nuclear staining cells using a multi-
headed microscope with both reviewers simultaneously
viewing the slides.
Statistical analysis
The statistical analysis was done with SPSS 15.0 program.
To assess the relationship between experimental results
and clinicopathologic characteristics, Fisher's exact test
and Spearman's ρ coefficients test were carried out as
appropriate. To find out the correlations between HIF-1α
and other evaluated factors, Pearson Correlation test was
used.
Table 1: Forward and reverse primers for the genes analyzed
Gene Forward primer Reverse primer
HIF-1α 5'CTGCTGTCTTACTGGTCCTT3' 5'GTCGCTTCTCCA ATTCTTAC3'
COX-2 5'CCATTCAGTTCCCACCATCT3' 5'TCACTGCTGTTGGGTCTCTG3'
MMP7 5'AGATGTGGAGTGCCAGATGT3' 5'TAGACTGCTACCATCCGTCC3'
MMP9 5'GGCGCTCATGTACCCTATGT3' 5'CCTGTGTACACCCACACCTG3'
VEGF 5'ATGAACTTTCTGCTCTCTGG3' 5'TCATCTCTCCTATGTGCTGGC3'
PDGFRA 5'GGGGAAACGATTGTGGTCACC3' 5'CCCGCACCTCTACAACAAAAT3'
MYC 5'AAAGGCCCCCAAGGTAGTTA3' 5'TTTCCGCAACAAGTCCTCTT3'
HPRT 5'CCTGGCGTCGTGATTAGTG3' 5'CAGAGGGCTACAATGTGATGG3'
TBP 5'ACCACTCCACTGTATCCCTCC3' 5'CTGTTCTTCACTCTTGGCTCCT3'BMC Cancer 2009, 9:418 http://www.biomedcentral.com/1471-2407/9/418
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Patient survival distribution was calculated using the Kap-
lan-Meier method and compared with the log-rank test.
Cut-point value of experiment results was determined by
the X-tile software [26]. Univariate and multivariate anal-
yses were based on the Cox proportional hazards regres-
sion model. All variables that were found to be statistical
significant in univariate analysis were included in multi-
variate analysis. P < 0.05 (two-sided) was judged statisti-
cally significant.
Results
Correlation of HIF-1  mRNA to clinicopathologic features
According to the optimal cut-point value of HIF-1α deter-
mined by the X-tile software, the expression of HIF-1α
mRNA was defined as high expression in 42 specimens
(38.2%) and low expression in 68 specimens (61.8%).
The HIF-1α mRNA expression level has no correlation to
gender, tumor size, encapsulation, number, hepatitis his-
tory, liver cirrhosis and preoperative AFP level, while older
patients seems to have tumor with higher HIF-1α expres-
sion (P = 0.049) (Table 2).
The HIF-1α mRNA expression level showed significantly
positive correlation with vascular invasion. In all the 110
patients, 59 cases without tumor vascular invasion have a
high expression rate of 28.8%, as compared with the high
expression rate of 49.0% (P = 0.033) in cases with vascular
invasion. Also, the HIF-1α mRNA expression level was sig-
nificantly correlated to BCLC stages. The HIF-1α mRNA
expression in patients at stage A was lower than those at
stages B and C (P = 0.041) (Table 2).
Correlation of HIF-1  to COX-2, MMP7, MMP9, VEGF, 
PDGFRA and MYC
Significant positive correlations were observed between
HIF-1α mRNA and the putative markers of inflammation,
angiogenesis and MYC: COX-2 (P < 0.001, r = 0.708),
MMP7 (P < 0.001, r = 0.593), MMP9 (P < 0.001, r =
0.384), PDGFRA (P < 0.001, r = 0.493) and MYC (P <
0.001, r = 0.230). However, there were no significant cor-
relation between mRNA expression level of HIF-1α and
VEGF (P < 0.183, r = 0.128). Of all the six parameters,
COX-2, MMP7 and PDGFRA were the top three factors
with the largest correlation coefficients to HIF-1α (Table
3).
Prognosis
The OS and DFS rates were 80.0% and 67.6% at 1 year,
and 51.4% and 43.7% at 5 years respectively, for the
whole study population.
On univariate analysis, sex, hepatitis history, cirrhosis,
ALT level showed no prognostic significance for OS and
DFS. AFP, γ-GT, tumor differentiation, size, vascular inva-
sion and encapsulation were found to be significant pre-
dictors for OS. Age, AFP, γ-GT, tumor size, number,
vascular invasion and encapsulation were predictors for
DFS (Table 4).
Univariate analysis revealed that the HIF-1α mRNA
expression level was associated with both OS (P = 0.001)
and DFS (P = 0.001) (Table 4; Figure 1A and 1B). The OS
rate for patients with high and low expression of HIF-1α
Table 2: Correlations of HIF-1α mRNA and protein with 
clinicopathological characters
HIF-1α mRNA HIF-1α protein
low high P low high P
Patients 68 42 71 39
Age(years)
≤52 28 26 0.049 32 22 0.320
> 5 2 4 01 6 3 91 7
Sex
Male 57 38 0.40 57 38 0.017
Female 11 4 14 1
Hepatitis history
Yes 61 39 0.739 62 38 0.094
No 7 3 9 1
Preoperative AFP(ng/ml)
≤20 29 16 0.693 33 12 0.156
> 2 0 3 92 6 3 82 7
Liver cirrhosis
Yes 59 34 0.428 56 37 0.029
No 9 8 15 2
ALT(U/L)
≤40 36 22 1.000 38 20 0.844
> 4 0 3 22 0 3 31 9
Γ-GT(U/L)
≤54 30 14 0.318 31 13 0.316
> 5 4 3 82 8 4 02 6
Tumor size (cm)
≤5 35 21 1.000 33 23 0.236
>5 33 21 38 16
Tumor encapsulation
Yes 31 18 0.845 32 17 1.000
No 37 24 39 22
Tumor number
Single 53 32 0.820 56 29 0.638
Multiple 15 10 15 10
Vascular invasion
Yes 26 25 0.033 27 24 0.027
No 42 17 44 15
BCLC stage
A 30 10 0.041 31 9 0.039
B  +  C 3 83 2 4 03 0
Tumor differentiation
I+II 40 18 0.119 36 22 0.690
III+IV 28 24 35 17
Prophylactic treatment
Yes 33 22 0.845 31 24 0.110
No 35 20 39 16
Detailed legends: Fisher's exact tests were used for all the analysis of 
correlations.BMC Cancer 2009, 9:418 http://www.biomedcentral.com/1471-2407/9/418
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mRNA were 63.2% and 88.9% at 1 year (P = 0.001),
30.4% and 62.5% at 5 year (P = 0.001) respectively. Sim-
ilarly, the DFS rate for patients with high and low expres-
sion were 53.9% and 74.3% at 1 year (P = 0.004), 20.4%
and 54.8% at 5 year (P = 0.004) respectively.
Further, multivariate analysis confirmed that HIF-1α
mRNA expression was independent prognostic factor for
OS (P = 0.012, hazard ratio: 2.167, 95%CI: 1.185-3.965)
and DFS (P = 0.004, hazard ratio: 2.359, 95%CI: 1.325-
4.201). In addition, for DFS, the P value was the smallest
and the hazard ratio was the largest among these factors
(Table 5 and Additional files 3, 4, 5, 6, 7 and 8 ).
Also, as for mRNA expression, COX-2 and PDGFRA, being
correlated with HIF-1α with larger coefficients among the
six parameters, showed significance for both OS and DFS
on univariate analysis (COX-2: P = 0.014 for OS, P = 0.027
for DFS; PDGFRA: P = 0.044 for OS, P = 0.041 for DFS)
and then strengthened on multivariate analysis (COX-2: P
= 0.004 for OS, P = 0.010 for DFS; PDGFRA: P = 0.010 for
OS, P = 0.038 for DFS). MMP7, which also correlated with
HIF-1α, showed significance for OS on both uni- and
multi-variate analyses, and patients with high MMP7 had
a propensity of increased recurrence (P = 0.060). How-
ever, VEGF was only significant for DFS (P = 0.022) but
has no influence on OS (P = 0.299) in univariate analysis.
On multivariate analysis, VEGF was not a significant prog-
nostic factor for recurrence (P = 0.081) any more. Neither
MMP9 (P = 0.313 for OS, P = 0.607 for DFS) nor MYC (P
= 0.862 for OS, P = 0.361 for DFS) had any prognostic
value for either OS or DFS in HCC. (Tables 4 and 5)
Table 3: Correlations between HIF-1α mRNA and other molecular markers as well as prognostic significance.
HIF-1α COX-2 MMP7 PDGFRA MMP9 MYC VEGF
Correlation (P) 0.000 < 0.001 < 0.001 < 0.001 < 0.001 0.016 0.183
Coefficient (r) 1.000 0.708 0.593 0.493 0.384 0.230 0.128
OS (P) 0.012 0.004 0.010 0.010 NS NS NS
DFS (P) 0.004 0.010 NS 0.038 NS NS NS
Detailed legends: The P values for correlation were determined by spearman's coefficience. The P values for OS and DFS were calculated using 
multivariate Cox proportional hazards analysis. All factors were presented in different multivariable analysis respectively and variables were 
adopted for their prognostic significance by univariate analysis. NS means not significant (P > 0.05).
Table 4: Univariate analyses of factors associated with survival and recurrence
Variables OS DFS
Hazard ratio(95%CI) P Hazard ratio(95%CI) P
Age (year) 0.982 (0.958-1.006) 0.142 0.976 (0.953-0.999) 0.043
Sex (female vs. male) 0.630 (0.250-1.588) 0.298 0.673 (0.288-1.574) 0.361
Hepatitis history (no vs. yes) 1.384 (0.498-3.848) 0.534 0.874 (0.395-1.935) 0.739
Liver cirrhosis (no vs. yes) 1.855 (0.746-4.657) 0.190 0.904 (0.455-1.797) 0.773
AFP(ng/ml) (≤ 20 vs. >20) 2.183 (1.175-4.035) 0.013 2.553 (1.401-4.651) 0.002
ALT(U/L) (≤ 40 vs. >40) 0.877 (0.502-1.533) 0.645 0.817 (0.476-1.401) 0.463
γ-GT(U/L) (≤ 54 vs. >54) 2.475 (1.313-4.664) 0.005 1.555 (0.888-2.722) 0.123
Tumor differentiation (I+II vs. III+IV) 1.860 (1.062-3.297) 0.030 1.180 (0.691-2.014) 0.545
Tumor size (cm) 1.179 (1.109-1.253) 0.001 1.152 (1.083-1.226) 0.001
Tumor number (single vs. multiple) 1.597 (0.860-2.966) 0.138 2.851 (1.611-5.046) 0.001
Vascular invasion (no vs. yes) 5.706 (2.971-10.960) 0.001 4.028 (2.288-7.089) 0.001
Encapsulation (complete vs. no) 2.060 (1.135-3.737) 0.017 3.273 (1.773-6.044) 0.001
BCLC stage (A vs. B+C) 6.225 (2.645-14.647) 0.001 2.601 (1.390-4.867) 0.003
COX-2 mRNA (low vs. high) 2.042 (1.157-3.604) 0.014 1.839 (1.068-3.167) 0.027
MMP7 mRNA (low vs. high) 2.278 (1.297-4.001) 0.004 0.753 (0.409-1.384) 0.060
MMP9 mRNA (low vs. high) 0.740 (0.412-1.328) 0.313 1.711 (0.977-2.995) 0.609
VEGF mRNA (low vs. high) 1.370 (0.756-2.483) 0.299 1.906 (1.096-3.126) 0.022
PDGFRA mRNA (low vs. high) 1.801 (1.017-3.188) 0.044 1.771 (1.023-3.066) 0.041
MYC mRNA (low vs. high) 0.948 (0.517-1.735) 0.862 0.867 (0.501-1.499) 0.361
HIF-1α mRNA (low vs. high) 2.644 (1.524-4.655) 0.001 2.514 (1.462-4.324) 0.001
HIF-1α protein (low vs. high) 1.874 (1.074-3.270) 0.027 2.004 (1.167-3.440) 0.012
Detailed legends: The P values were calculated using univariate Cox proportional hazards analysis. Cut-point values of the experiment results were 
determined by the X-tile software.BMC Cancer 2009, 9:418 http://www.biomedcentral.com/1471-2407/9/418
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Immunohistochemical confirmation
In HCC, positive staining of HIF-1α protein was observed
mainly in cancer cells, and occasionally in infiltrating
lymphocytes as well. In contrast, the fibroblasts and
endothelial cells in tumor tissue always showed negative
staining. HIF-1α protein was commonly detected in cyto-
plasm, whereas in some cases HIF-1α protein was
detected mostly in nucleus. Representative images were
showed in Figure 2.
According to the optimal cut-point determined by the X-
tile software, there were 71 (64.5%) patients with low
expression and 39 (35.5%) patients with high expression.
Although the immunohistochemical results were not
totally in parallel with the RT-PCR results, protein expres-
sion of HIF-1α were highly correlated with the mRNA
expression (P = 0.001). (See Additional file 9: Table S2 for
correlations between HIF-1α mRNA and protein)
Kaplan-Meier analysis of overall and disease-free survival for HIF-1α mRNA and protein Figure 1
Kaplan-Meier analysis of overall and disease-free survival for HIF-1α mRNA and protein. Low expression of HIF-
1α mRNA (A, B) or protein (C, D) was associated with both prolonged survival and reduced recurrence. The P values were 
determined by the log-rank test.BMC Cancer 2009, 9:418 http://www.biomedcentral.com/1471-2407/9/418
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The tumor HIF-1α protein expression level has no associ-
ation with patient age, tumor size, number, encapsula-
tion, hepatitis history and preoperative AFP. Similar to
HIF-1α mRNA, the tumor HIF-1α protein expression level
was significantly associated with tumor vascular invasion
(P = 0.027) and BCLC stages (P = 0.039). (Table 2)
High expression of protein also means the poor outcome.
Both OS and DFS were better in low expression group
than that of high expression group. The OS rates for
patient with high and low expression of HIF-1α protein
were 69.2% and 85.9% at 1 year (P = 0.015), 39.8% and
58.0% at 5 years (P = 0.015) respectively. Also, the DFS
rates for high and low expression were 50.8% and 76.5%
at 1 year (P = 0.009), 30.3% and 51.2% at 5 year (P =
0.009) respectively.
On univariate analysis, tumor HIF-1α protein expression
level was significant for both OS (P = 0.027) and DFS (P
= 0.012) (Table 4; Figure 1C and 1D), which were further
authenticated on multivariate analysis (P = 0.021 for OS;
P = 0.007 for DFS) (Table 5). These may indicate that the
prognostic value of HIF-1α was further validated on pro-
tein level.
Discussion
It has been established that human solid tumors develop
a pathophysiologic microenvironment during growth,
characterized by an irregular microvascular network and
regions of hypoxia [7]. Of clinical importance, hypoxia-
related genes and proteins are potentially alternative
endogenous markers, as compared with the inability and
the cost of exogenous hypoxia markers [2]. In this study,
we demonstrated for the first time that HIF-1α, at both
mRNA and protein levels, is an independent prognostic
factor for both survival and recurrence in HCC with the
smallest P  value as well as the largest hazard ratio for
recurrence. In addition, we found that high expression of
HIF-1α was significantly associated with an advanced
stage and aggressive phenotypes. Several in vitro experi-
mental studies sustained our results. In rat HCC models,
tumor progression after hypoxia and chemotherapy was
related to up-regulation of HIF-1α and subsequent VEGF
production, and transcriptional blockade of HIF-1α could
enhance their therapeutic efficacy [27]. In cell lines, HCC
cell proliferation was inhibited by HIF-1α antisense oligo-
nuclecotide [28]. As a key player in tumor progression,
HIF-1α overexpression is associated with an increased
mortality and treatment failure in various cancers
Table 5: Multivariate analyses of factors associated with survival and recurrence
Hazard ratio (95%CI) P
OS
AFP(ng/ml) (≤ 20 vs. >20) 1.320 (0.666-2.615) 0.426
γ-GT(U/I) (≤ 54 vs. >54) 2.098 (1.073-4.103) 0.030
Tumor differentiation (I+II vs. III+IV) 1.228 (0.661-2.279) 0.516
Tumor size (cm) 1.102 (1.016-1.196) 0.020
Vascular invasion (no vs. yes) 4.351 (1.992-9.500) 0.001
Capsule (complete vs. no) 0.676 (0.332-1.375) 0.280
HIF-1α mRNA (low vs. high) 2.167 (1.185-3.965) 0.012
COX-2 mRNA (low vs. high) 2.557 (1.355-4.824) 0.004
MMP7 mRNA (low vs. high) 2.287 (1.217-4.301) 0.010
PDGFRA mRNA (low vs. high) 2.320 (1.225-4.394) 0.010
HIF-1α protein (low vs. high) 2.108 (1.120-3.969) 0.021
DFS
Age (year) 0.990 (0.963-1.018) 0.475
AFP(ng/ml) (≤ 20 vs. >20) 1.707 (0.903-3.227) 0.100
Tumor size (cm) 1.090 (0.997-1.191) 0.060
Tumor number (single vs. multiple) 3.324 (1.818-6.079) 0.001
Vascular invasion (no vs. yes) 2.453 (1.192-5.047) 0.015
Encapsulation (complete vs. no) 1.573 (0.781-3.168) 0.204
HIF-1α mRNA (low vs. high) 2.359 (1.325-4.201) 0.004
COX-2 mRNA (low vs. high) 2.170 (1.201-3.921) 0.010
MMP7 mRNA (low vs. high) 1.499 (0.830-2.707) 0.179
VEGF mRNA (low vs. high) 1.702 (0.936-3.094) 0.081
PDGFRA mRNA (low vs. high) 1.910 (1.038-3.514) 0.038
HIF-1α protein (low vs. high) 2.265 (1.251-4.009) 0.007
Detailed legends: The P values were calculated using multivariate Cox proportional hazards analysis. Variables were adopted for their prognostic 
significance by univariate analysis and no significant correlation between each other. COX-2 mRNA, PDGFRA mRNA, MMP7 mRNA, VEGF mRNA 
and HIF-1α protein were presented in different multivariable analysis respectively. (For details see Additional files 3, 4, 5, 6, 7 and 8)BMC Cancer 2009, 9:418 http://www.biomedcentral.com/1471-2407/9/418
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although conflicting data exist [7]. The current study
emphasizes the clinical significance of HIF-1α, suggesting
that related therapy in the future is promising in reducing
recurrence and prolonging survival [29].
The underlying mechanisms that HIF-1α affects meta-
static spread and selecting cells with more aggressive phe-
notypes have not been fully defined, but recent studies
have shown a role for increased invasive capacity and
inflammation [11]. Consistently, we found the impor-
tance of HIF-1α in HCC is associated with or may contrib-
ute to other markers related to inflammation,
angiogenesis and invasion. COX-2, MMP7 and MMP9
were well-recognized factors in inflammation conditions
[14-16]. Among these molecules, COX-2, being involved
in the chronic inflammation-related development of
HCC, correlated with HIF-1α with the largest correlation
coefficient (r = 0.708). Mechanistically, hypoxia potently
triggers COX-2 transcription in many kinds of cells in pri-
mary culture [30,31]. Also, hypoxia influences the expres-
sion of MMPs although the mechanisms are controversial
[5,32]. The mRNA expression of MMP7, which can
degrade various ECM proteins and support the role in
tumor invasion and spread in HCC, has significant corre-
lation to HIF-1α mRNA expression in our study (r  =
0.593). However, MMP9, without any prognostic signif-
cance, seems to have less significant correlation to HIF-1α
mRNA than MMP7 in HCC (r = 0.383). VEGF and PDG-
FRA promote the tumor angiogenesis in inflammation
and hypoxia conditions [18,33]. HIF-1α was often consid-
ered a master regulator of VEGF expression and angiogen-
esis in hypoxia. However, in our study, VEGF has no
significant correlations with HIF-1α. As suggested, the reg-
ulation of VEGF expression may be come true by HIF-1α-
independent pathways in hypoxia [34]. Otherwise, stud-
ies have revealed hypoxia can upregulate the expression of
PDGFA [10], PDGFB [35] and PDGFRB [36], with little
information on the correlation between HIF-1α and PDG-
FRA. Our study provide the preliminary data that HIF-1α
positively correlated with and thus may upregulate PDG-
FRA, also a crucial angiogenic factor, in HCC (P < 0.001, r
= 0.493).
All of these factors were conceived to promote tumor pro-
gression. Some of these molecules, such as COX-2, PDG-
FRA and MMP7, were believed to be prognostic factors in
HCC according to our research. COX-2 may regulate HCC
growth by COX-2-derived PG signaling pathway [37].
PDGFRA may regulate tumor angiogenesis by PDGFRA-
p70S6K pathway which is related to the function of
fibroblast growth factor (FGF) and expression of VEGF
and hepatocytes growth factor (HGF) [18]. MMPs increase
HCC invasion and growth through the degradation of
extracellar matrix [38].
However, we propose that HIF-1α, with the smallest P
value as well as the largest hazard ratio for DFS among
these factors, may be the central factor to affect HCC out-
come. Extensive researches have confirmed that HIF-1α
controls many hundreds of target genes which play
important roles in the cellular adaptation to hypoxia, and
the proteins of these genes are involved in processes
which can make cancer cells much more aggressive, such
as angiogenesis, proliferation, apoptosis, energy metabo-
lism and glucose transportation [29].
In addition, the oncogene MYC also plays a crucial role in
hypoxic response, and cooperates with HIF-1α to alter cel-
lular metabolism and promote cancer progression [19]. In
our study, MYC was positive correlated with HIF-1α (P =
0.016). However, the correlation coefficient was small (r
= 0.230), and MYC has no prognostic value in HCC. The
findings that MYC expression was repressed in the human
hepatoma cell lines under extremely low oxygen concen-
Representative images of immunohistochemical staining Figure 2
Representative images of immunohistochemical 
staining. A: Negative expression of HIF-1α protein (× 200). 
B: Positive expression of HIF-1α protein (× 200). C: HIF-1α 
protein localized in the cytoplasm (× 400). D: HIF-1α protein 
localized in the nucleus (arrows) (× 400). E: Negative staining 
in fibroblasts and endothelial cells (arrows) (× 400). F: Posi-
tive staining in lymphocytes (arrows) (× 400).BMC Cancer 2009, 9:418 http://www.biomedcentral.com/1471-2407/9/418
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trations may partly responsible for this non-significance
[39].
In summary, HIF-1α was an independent prognosticator
for both survival and recurrence in HCC. Although the
correlations between HIF-1α and markers of inflamma-
tion, angiogenesis and the cooperative MYC oncogene are
not very clear, we can hypothesize that HIF-1α was the
crucial factor in HCC progression on the basis of our find-
ings. The therapy targeting HIF-1α and associated mole-
cules may profoundly reduce recurrence and prolong
survival.
Conclusion
HIF-1α was an independent prognosticator for both sur-
vival and recurrence in HCC. Markers of inflammation,
angiogenesis and the cooperative MYC oncogene, who
have closer correlation with HIF-1α, seem to be better for
prognostic stratification, suggesting that HIF-1α was one
of the most crucial factors in HCC progression. Attaching
importance to HIF-1α and related molecules may
improve the prognostic stratification and therapeutic
technique.
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